Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vyndaqel

- PMLiVE

Pfizer and Flynn accused of overcharging for epilepsy drug

UK watchdog investigating the firms over the millions of pounds spent on Epanutin

- PMLiVE

Pfizer links with Synthon on generic Copaxone

US giant looking to grab a share of the copycat market for the MS drug

- PMLiVE

Pfizer takes MRSA vaccine into phase IIb trial

Trial will involve patients undergoing elective spinal fusion surgery

- PMLiVE

AstraZeneca’s Amie Baker wins Communiquétor 2015 award

And the UK pharma company takes home In-House team of the Year

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

- PMLiVE

Executive leak continues at AZ as another head jumps ship

James Ward-Lilley will become CEO of lung drug specialist Vectura

- PMLiVE

US expands recommended use of meningitis B vaccines

Butopts not to back routine use of GSK's Bexsero and Pfizer' Trumenba

- PMLiVE

NICE recommends infliximab biosimilars ahead of Remicade

Newly-acquired Hospira and Napp see their infliximab products backed by the HTA body

- PMLiVE

Pharma set for a strong 2015 as drug sales jump

Industry looking to put the recent ‘horror’ patent expiry years behind it

Eli Lilly HQ

Lilly and Incyte’s baricitinib aces phase III trials

Supports its potential as a therapy for rheumatoid arthritis

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

- PMLiVE

Pfizer ‘bids €1.5bn’ for CAR-T specialist Cellectis

French immuno-oncology biotech reported to be next on pharma giant's hit list

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links